Archive: 08/08/2022
Sugemalimab: safe and effective consolidation therapy for patients with unresectable Stage III NSCLC
The human monoclonal antibody sugemalimab is a safe and effective consolidation therapy for patients with unresectable stage III non-small cell lung cancer without disease progression after either concurrent chemoradiotherapy ...
Aug 8, 2022